Cannabis Policy Needs to Balance Psychosis Risk with Medicinal Potential

Cannabis use increases the risk of psychosis, but cannabis-based medicinal products may provide additional therapeutic opportunities. The author notes a policy paradox: decriminalization has led to wider recreational availability in some jurisdictions, while in the UK, regulated medicinal preparations remain difficult to access. A more balanced approach could reduce harms while maximizing potential therapeutic benefits.

Editorial commentary in the British Journal of Psychiatry examining the tension between cannabis-related psychosis risk and medicinal cannabis potential, with policy recommendations.

This perspective from a leading psychiatric journal frames the cannabis policy challenge clearly: the same plant that poses psychosis risks also contains compounds with therapeutic potential. Policies that address only one side of this equation miss the full picture.

The editorial reflects a growing recognition in mainstream psychiatry that cannabis policy must be more nuanced than simply "for" or "against." The challenge is creating regulatory frameworks that minimize harm from high-potency recreational products while facilitating access to standardized medicinal preparations.

Brief editorial commentary (1-2 pages) rather than a comprehensive review. Represents one author's perspective. UK-focused policy discussion may not directly apply to other jurisdictions.